系统性红斑狼疮的靶向药物研究进展  

Progress in targeted drug of systemic lupus erythematosus

作　　者：张艳艳 潘绵立[1] 沈龙海[1] ZHANG Yanyan;PAN Mianli;SHEN Longhai(State Key Laboratory of New Drug and Pharmaceutical Process-Shanghai Professional and Technical Service Center for Biological Material Drug Gability Evaluation,Shanghai Institute of Pharmaceutical Industry,China State Institute of Pharmaceutical Industry,Shanghai 200437,China)

机构地区：[1]上海医药工业研究院创新药物与制药工艺国家重点实验室,上海市生物物质成药性评价专业技术服务平台,上海200437

出　　处：《世界临床药物》2021年第2期143-148,共6页World Clinical Drug

摘　　要：系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种以多器官损伤为特征的慢性自身免疫性疾病,发病原因较复杂。目前SLE的全球发病率逐年上升,且具有较高的死亡率。由于该疾病存在异质性,临床仍无较确切的治疗方法。本文就近年SLE治疗药物开发现状作一综述,旨在为临床诊治SLE提供参考。Systemic lupus erythematosus(SLE) is a chronic autoimmune disease characterized by multiple organ damage with complex causes.At present,the world morbidity rate of SLE is increasing year by year and has a high mortality rate.Due to the heterogeneity of the disease,there is still no effective treatment methods and means in clinic.This article reviewed the current status of drug development in SLE to provide reference for clinical diagnosis and treatment of SLE.

关 键 词：系统性红斑狼疮 免疫异常 靶向药物 

分 类 号：R593.241[医药卫生—内科学]